Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey.

Lancaster LH, Valenzuela C, Mason W, Neurohr C, Ripamonti E, Kirchgaessler KU, Cottin V.

Pulm Ther. 2020 Mar 19. doi: 10.1007/s41030-020-00111-y. [Epub ahead of print]

PMID:
32193713
2.

Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial ILD.

Salisbury ML, Hewlett JC, Ding G, Markin CR, Douglas K, Mason W, Guttentag A, Phillips JA 3rd, Cogan JD, Reiss S, Mitchell DB, Wu P, Young LR, Lancaster LH, Loyd JE, Humphries SM, Lynch DA, Kropski JA, Blackwell TS.

Am J Respir Crit Care Med. 2020 Feb 3. doi: 10.1164/rccm.201909-1834OC. [Epub ahead of print]

PMID:
32011901
3.

Patient Registries in Idiopathic Pulmonary Fibrosis.

Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):160-167. doi: 10.1164/rccm.201902-0431CI. Review.

4.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW.

Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available.

5.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

6.

Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis.

Lancaster LH.

Multidiscip Respir Med. 2018 Dec 13;13:45. doi: 10.1186/s40248-018-0158-z. eCollection 2018. Review.

7.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

8.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

9.

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL.

Lancet Respir Med. 2018 Aug;6(8):603-614. doi: 10.1016/S2213-2600(18)30135-8. Epub 2018 Jun 18.

10.

Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease.

Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, Duffy J, Gaston B, Heller NM, Hemnes A, Henske EP, Jain R, Lahm T, Lancaster LH, Lee J, Legato MJ, McKee S, Mehra R, Morris A, Prakash YS, Stampfli MR, Gopal-Srivastava R, Laposky AD, Punturieri A, Reineck L, Tigno X, Clayton J.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):850-858. doi: 10.1164/rccm.201801-0168WS. Review.

11.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

12.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

13.

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):94-103. doi: 10.1164/rccm.201704-0784OC.

PMID:
28787186
14.

Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.

Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM.

Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24.

15.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
16.

Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis.

Kropski JA, Young LR, Cogan JD, Mitchell DB, Lancaster LH, Worrell JA, Markin C, Liu N, Mason WR, Fingerlin TE, Schwartz DA, Lawson WE, Blackwell TS, Phillips JA 3rd, Loyd JE.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1423-1428. doi: 10.1164/rccm.201609-1820PP. No abstract available.

17.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

18.

Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.

Meyer KC, Danoff SK, Lancaster LH, Nathan SD.

Chest. 2015 Jul;148(1):242-252. doi: 10.1378/chest.14-2475. Review.

PMID:
26149553
19.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.

20.

Rare variants in RTEL1 are associated with familial interstitial pneumonia.

Cogan JD, Kropski JA, Zhao M, Mitchell DB, Rives L, Markin C, Garnett ET, Montgomery KH, Mason WR, McKean DF, Powers J, Murphy E, Olson LM, Choi L, Cheng DS, Blue EM, Young LR, Lancaster LH, Steele MP, Brown KK, Schwarz MI, Fingerlin TE, Schwartz DA, Lawson WE, Loyd JE, Zhao Z, Phillips JA 3rd, Blackwell TS.

Am J Respir Crit Care Med. 2015 Mar 15;191(6):646-55. doi: 10.1164/rccm.201408-1510OC.

21.

Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease.

Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, McMahon FB, Worrell JA, Solus JF, Ware LB, Lee JW, Massion PP, Zaynagetdinov R, White ES, Kurtis JD, Johnson JE, Groshong SD, Lancaster LH, Young LR, Steele MP, Phillips Iii JA, Cogan JD, Loyd JE, Lawson WE, Blackwell TS.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):417-26. doi: 10.1164/rccm.201406-1162OC.

22.

Bronchoscopic cryobiopsy for the diagnosis of diffuse parenchymal lung disease.

Kropski JA, Pritchett JM, Mason WR, Sivarajan L, Gleaves LA, Johnson JE, Lancaster LH, Lawson WE, Blackwell TS, Steele MP, Loyd JE, Rickman OB.

PLoS One. 2013 Nov 12;8(11):e78674. doi: 10.1371/journal.pone.0078674. eCollection 2013.

23.

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA.

Nat Genet. 2013 Jun;45(6):613-20. doi: 10.1038/ng.2609. Epub 2013 Apr 14. Erratum in: Nat Genet. 2013 Nov;45(11):1409.

24.

Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.

Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, Lancaster LH, Wolters PJ, DeRisi J, Ganem D, Collard HR.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1698-702. doi: 10.1164/rccm.201010-1752OC. Epub 2011 Feb 25.

25.

Obstructive sleep apnea is common in idiopathic pulmonary fibrosis.

Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA.

Chest. 2009 Sep;136(3):772-778. doi: 10.1378/chest.08-2776. Epub 2009 Jun 30.

26.

Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury.

Garantziotis S, Zudaire E, Trempus CS, Hollingsworth JW, Jiang D, Lancaster LH, Richardson E, Zhuo L, Cuttitta F, Brown KK, Noble PW, Kimata K, Schwartz DA.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):939-47. doi: 10.1164/rccm.200803-386OC. Epub 2008 Aug 14.

27.

Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.

Collard HR, Loyd JE, King TE Jr, Lancaster LH.

Respir Med. 2007 Sep;101(9):2011-6. Epub 2007 May 16.

28.

Suppression of lung inflammation in rats by prevention of NF-kappaB activation in the liver.

Lancaster LH, Christman JW, Blackwell TR, Koay MA, Blackwell TS.

Inflammation. 2001 Feb;25(1):25-31.

PMID:
11293663
29.

Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation.

Blackwell TS, Yull FE, Chen CL, Venkatakrishnan A, Blackwell TR, Hicks DJ, Lancaster LH, Christman JW, Kerr LD.

Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1095-101.

PMID:
10988136
30.

Differential NF-kappaB activation after intratracheal endotoxin.

Blackwell TS, Lancaster LH, Blackwell TR, Venkatakrishnan A, Christman JW.

Am J Physiol. 1999 Oct;277(4):L823-30. doi: 10.1152/ajplung.1999.277.4.L823.

PMID:
10516225
31.

Use of genetically altered mice to investigate the role of nuclear factor-kappa B activation and cytokine gene expression in sepsis-induced ARDS.

Blackwell TS, Yull FE, Chen CL, Venkatakrishnan A, Blackwell TR, Hicks DJ, Lancaster LH, Christman JW, Kerr LD.

Chest. 1999 Jul;116(1 Suppl):73S-74S. No abstract available.

PMID:
10424600
32.

Chemotactic gradients predict neutrophilic alveolitis in endotoxin-treated rats.

Blackwell TS, Lancaster LH, Blackwell TR, Venkatakrishnan A, Christman JW.

Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1644-52.

PMID:
10228139
33.

Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy.

Christman JW, Lancaster LH, Blackwell TS.

Intensive Care Med. 1998 Nov;24(11):1131-8. Review.

Supplemental Content

Loading ...
Support Center